AMRI buys Hyaluron to enter prefilled syringe market

By Nick Taylor

- Last updated on GMT

Related tags: Syringe

AMRI has acquired Hyaluron for $27m (€22m) to enter the prefilled syringe market and expand the customer base for its existing operations.

Acquiring Hyaluron gives AMRI capacity for current good manufacturing practice (cGMP) production and sterile filling of parenteral drugs. This moves AMRI into the prefillable syringe contract manufacturing sector, which is set to grow as biologics use increases.

Having made the buy AMRI is able to offer clients a fully integrated production process for sterile injectables. This includes development and manufacture of active pharmaceutical ingredients (API), design of the criteria to formulate the injectable, and production of the finished product.

We believe that the unique capabilities of both organisations will quickly assimilate into a larger, fully integrated GMP manufacturing provider of choice for companies desiring to capitalise on seamless technology transfer​”, said Thomas D’Ambra, CEO of AMRI.

The benefits of this integration include “increased efficiency and cost benefits​”, said D’Ambra.

The deal

AMRI has paid $27m, including debt, to acquire Hyaluron’s facilities, equipment and staff. The deal includes the patented Bubble-Free Filling technology developed and owned by Hyaluron.

Using the vacuum filling and stoppering technology Hyaluron can fill products without gas bubbles. This is beneficial when handling oxygen sensitive compounds, such as proteins, which can become less stable when exposed to oxygen.

Furthermore, Bubble-Free Filling creates an unfavourable environment for the growth of microorganisms and reduces the threat to sterility caused by accidental low level contamination.

Capabilities

From its site in Burlington, Massachusetts, US Hyaluron provides filling of liquid and lyophilised products into syringes, vials and custom containers. This can be preformed at scales ranging from preclinical to commercial.

Particular expertise includes process development for difficult formulations, such as emulsions, viscous gels, suspensions, liposomes and proteins. Hyaluron also provides stability testing for clients to evaluate the shelf-life of products in different containers, such as vials and syringes.

Related news

Show more

Related products

show more

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

baxter_bloomington_facility_larger

Sterile Injectables Contract Manufacturing

Baxter BioPharma Solutions | 02-Apr-2018 | Product Brochure

Baxter BioPharma Solutions' award-winning facility in Bloomington, Indiana, USA, is a leader in sterile contract manufacturing of injectable products.

Leveraging Best Practices in Primary Packaging

Leveraging Best Practices in Primary Packaging

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...

Related suppliers

Follow us

Products

View more

Webinars